Abstract

We read with interest the letter to the editor titled “Comments on A Conceptual Framework for Life-Cycle Health Technology Assessment” in response to our recent article published in Value in Health.1
 
We thank the authors for their analysis of our work and for their endorsement of the life-cycle health technology assessment (LC-HTA) framework. In response, we clarify the need for de novo model development as part of research-oriented market access, as well as some critical aspects of the risk-based price.